tiprankstipranks
Progyny, Inc. (PGNY)
NASDAQ:PGNY
US Market
PGNY
Progyny
RESEARCH TOOLSreports
Want to see PGNY full AI Analyst Report?

Progyny (PGNY) Stock Forecast & Price Target

699 Followers
See the Price Targets and Ratings of:

PGNY Analyst Ratings

Strong Buy
10Ratings
Strong Buy
8 Buy
2 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Progyny
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

PGNY Stock 12 Month Forecast

Average Price Target

$33.00
▲(5.80% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Progyny in the last 3 months. The average price target is $33.00 with a high forecast of $40.00 and a low forecast of $27.00. The average price target represents a 5.80% change from the last price of $31.19.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"$15","28":"$28","41":"$41","21.5":"$21.5","34.5":"$34.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$33.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$27.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,21.5,28,34.5,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.13,31.81230769230769,32.494615384615386,33.176923076923075,33.85923076923077,34.54153846153846,35.223846153846154,35.90615384615384,36.58846153846154,37.27076923076923,37.95307692307692,38.635384615384616,39.31769230769231,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.13,31.273846153846154,31.417692307692306,31.56153846153846,31.705384615384613,31.84923076923077,31.993076923076924,32.136923076923075,32.28076923076923,32.424615384615386,32.56846153846154,32.71230769230769,32.856153846153845,{"y":33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.13,30.81230769230769,30.494615384615383,30.176923076923075,29.85923076923077,29.54153846153846,29.223846153846154,28.906153846153845,28.588461538461537,28.27076923076923,27.95307692307692,27.635384615384616,27.317692307692308,{"y":27,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.49,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.41,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.22,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.71,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.27,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.68,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.21,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.6,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.86,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.6,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.2,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.45,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.13,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$40.00Average Price Target$33.00Lowest Price Target$27.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on PGNY
Peter Warendorf
Barclays
Barclays
$34→$30
Hold
-3.82%
Downside
Reiterated
08/12/26
Progyny (PGNY) Receives a Hold from Barclays
Canaccord Genuity Analyst forecast on PGNY
Richard Close
Canaccord Genuity
Canaccord Genuity
$35
Buy
12.22%
Upside
Reiterated
08/11/26
Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (NASDAQ: GUTS), Progyny (NASDAQ: PGNY) and Adicet Bio (NASDAQ: ACET)
Bank of America Securities Analyst forecast on PGNY
Allen Lutz
Bank of America Securities
Bank of America Securities
$31
Buy
-0.61%
Downside
Reiterated
08/07/26
Allen Lutz Reiterates Buy on Progyny, Maintains $31 Price Target Amid Strong Q2 and Robust Selling Season
Truist Financial Analyst forecast on PGNY
Jailendra Singh
Truist Financial
Truist Financial
―
Buy
―
Reiterated
08/07/26
Analysts Offer Insights on Healthcare Companies: Progyny (NASDAQ: PGNY), Scholar Rock Holding (NASDAQ: SRRK) and Ascendis Pharma (NASDAQ: ASND)
Cantor Fitzgerald Analyst forecast on PGNY
Sarah James
Cantor Fitzgerald
Cantor Fitzgerald
$31
Buy
-0.61%
Downside
Reiterated
08/06/26
Cantor Fitzgerald Sticks to Its Buy Rating for Progyny (PGNY)
BTIG Analyst forecast on PGNY
David Larsen
BTIG
BTIG
$30→$40
Buy
28.25%
Upside
Reiterated
07/24/26
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (NASDAQ: VKTX), Summit Therapeutics (NASDAQ: SMMT) and Progyny (NASDAQ: PGNY)
Leerink Partners Analyst forecast on PGNY
Michael Cherny
Leerink Partners
Leerink Partners
$30→$38
Buy
21.83%
Upside
Reiterated
07/22/26
Progyny price target raised to $38 from $30 at LeerinkProgyny price target raised to $38 from $30 at Leerink
KeyBanc Analyst forecast on PGNY
Scott Schoenhaus
KeyBanc
KeyBanc
$30→$35
Buy
12.22%
Upside
Reiterated
07/13/26
Analysts Offer Insights on Healthcare Companies: Progyny (NASDAQ: PGNY), Eli Lilly & Co (NYSE: LLY) and Madrigal Pharmaceuticals (NASDAQ: MDGL)
J.P. Morgan Analyst forecast on PGNY
Lisa Gill
J.P. Morgan
J.P. Morgan
$27
Hold
-13.43%
Downside
Reiterated
07/06/26
Analysts Offer Insights on Healthcare Companies: Progyny (NASDAQ: PGNY) and Neurocrine (NASDAQ: NBIX)
Goldman Sachs Analyst forecast on PGNY
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
$30
Buy
-3.82%
Downside
Upgraded
05/19/26
Positive Report for Progyny (PGNY) from Goldman Sachs
Citizens JMP Analyst forecast on PGNY
Constantine Davides
Citizens JMP
Citizens JMP
$30→$31
Buy
-0.61%
Downside
Reiterated
05/11/26
Progyny price target raised to $31 from $30 at CitizensProgyny price target raised to $31 from $30 at Citizens
Jefferies Analyst forecast on PGNY
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$33
Buy
5.80%
Upside
Reiterated
11/19/25
Progyny (PGNY) Receives a Buy from Jefferies
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on PGNY
Peter Warendorf
Barclays
Barclays
$34→$30
Hold
-3.82%
Downside
Reiterated
08/12/26
Progyny (PGNY) Receives a Hold from Barclays
Canaccord Genuity Analyst forecast on PGNY
Richard Close
Canaccord Genuity
Canaccord Genuity
$35
Buy
12.22%
Upside
Reiterated
08/11/26
Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (NASDAQ: GUTS), Progyny (NASDAQ: PGNY) and Adicet Bio (NASDAQ: ACET)
Bank of America Securities Analyst forecast on PGNY
Allen Lutz
Bank of America Securities
Bank of America Securities
$31
Buy
-0.61%
Downside
Reiterated
08/07/26
Allen Lutz Reiterates Buy on Progyny, Maintains $31 Price Target Amid Strong Q2 and Robust Selling Season
Truist Financial Analyst forecast on PGNY
Jailendra Singh
Truist Financial
Truist Financial
―
Buy
―
Reiterated
08/07/26
Analysts Offer Insights on Healthcare Companies: Progyny (NASDAQ: PGNY), Scholar Rock Holding (NASDAQ: SRRK) and Ascendis Pharma (NASDAQ: ASND)
Cantor Fitzgerald Analyst forecast on PGNY
Sarah James
Cantor Fitzgerald
Cantor Fitzgerald
$31
Buy
-0.61%
Downside
Reiterated
08/06/26
Cantor Fitzgerald Sticks to Its Buy Rating for Progyny (PGNY)
BTIG Analyst forecast on PGNY
David Larsen
BTIG
BTIG
$30→$40
Buy
28.25%
Upside
Reiterated
07/24/26
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (NASDAQ: VKTX), Summit Therapeutics (NASDAQ: SMMT) and Progyny (NASDAQ: PGNY)
Leerink Partners Analyst forecast on PGNY
Michael Cherny
Leerink Partners
Leerink Partners
$30→$38
Buy
21.83%
Upside
Reiterated
07/22/26
Progyny price target raised to $38 from $30 at LeerinkProgyny price target raised to $38 from $30 at Leerink
KeyBanc Analyst forecast on PGNY
Scott Schoenhaus
KeyBanc
KeyBanc
$30→$35
Buy
12.22%
Upside
Reiterated
07/13/26
Analysts Offer Insights on Healthcare Companies: Progyny (NASDAQ: PGNY), Eli Lilly & Co (NYSE: LLY) and Madrigal Pharmaceuticals (NASDAQ: MDGL)
J.P. Morgan Analyst forecast on PGNY
Lisa Gill
J.P. Morgan
J.P. Morgan
$27
Hold
-13.43%
Downside
Reiterated
07/06/26
Analysts Offer Insights on Healthcare Companies: Progyny (NASDAQ: PGNY) and Neurocrine (NASDAQ: NBIX)
Goldman Sachs Analyst forecast on PGNY
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
$30
Buy
-3.82%
Downside
Upgraded
05/19/26
Positive Report for Progyny (PGNY) from Goldman Sachs
Citizens JMP Analyst forecast on PGNY
Constantine Davides
Citizens JMP
Citizens JMP
$30→$31
Buy
-0.61%
Downside
Reiterated
05/11/26
Progyny price target raised to $31 from $30 at CitizensProgyny price target raised to $31 from $30 at Citizens
Jefferies Analyst forecast on PGNY
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$33
Buy
5.80%
Upside
Reiterated
11/19/25
Progyny (PGNY) Receives a Buy from Jefferies
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Progyny

3 Months
Sarah JamesCantor Fitzgerald
Success Rate
7/14 ratings generated profit
50%
Average Return
+6.86%
Copying Sarah James's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +6.86% per trade.
1 Year
Sarah JamesCantor Fitzgerald
Success Rate
9/14 ratings generated profit
64%
Average Return
+25.26%
Copying Sarah James's trades and holding each position for 1 Year would result in 64.29% of your transactions generating a profit, with an average return of +25.26% per trade.
2 Years
Allen LutzBank of America Securities
Success Rate
13/18 ratings generated profit
72%
Average Return
+13.08%
Copying Allen Lutz's trades and holding each position for 2 Years would result in 72.22% of your transactions generating a profit, with an average return of +13.08% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PGNY Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
6
4
0
0
0
Buy
2
10
11
15
11
Hold
4
3
1
3
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
12
17
12
18
15
In the current month, PGNY has received 11 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. PGNY average Analyst price target in the past 3 months is 33.00.
Each month's total comprises the sum of three months' worth of ratings.

PGNY Financial Forecast

PGNY Earnings Forecast

Next quarter’s earnings estimate for PGNY is $0.32 with a range of $0.29 to $0.35. The previous quarter’s EPS was $0.34. PGNY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year PGNY has Performed in-line its overall industry.
Next quarter’s earnings estimate for PGNY is $0.32 with a range of $0.29 to $0.35. The previous quarter’s EPS was $0.34. PGNY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year PGNY has Performed in-line its overall industry.

PGNY Sales Forecast

Next quarter’s sales forecast for PGNY is $342.61M with a range of $336.50M to $352.00M. The previous quarter’s sales results were $350.51M. PGNY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 66.67% of the time in the same period. In the last calendar year PGNY has Performed in-line its overall industry.
Next quarter’s sales forecast for PGNY is $342.61M with a range of $336.50M to $352.00M. The previous quarter’s sales results were $350.51M. PGNY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 66.67% of the time in the same period. In the last calendar year PGNY has Performed in-line its overall industry.

PGNY Stock Forecast FAQ

What is PGNY’s average 12-month price target, according to analysts?
Based on analyst ratings, Progyny, Inc.’s 12-month average price target is 33.00.
    What is PGNY’s upside potential, based on the analysts’ average price target?
    Progyny, Inc. has 5.80% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is PGNY a Buy, Sell or Hold?
          Progyny, Inc. has a consensus rating of Strong Buy which is based on 8 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Progyny, Inc.’s price target?
            The average price target for Progyny, Inc. is 33.00. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $40.00 ,the lowest forecast is $27.00. The average price target represents 5.80% Increase from the current price of $31.19.
              What do analysts say about Progyny, Inc.?
              Progyny, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of PGNY?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.